Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

3 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 2

1(20.0%)

Phase 4

1(20.0%)

Phase 1

1(20.0%)

5Total

Phase 3(2)

Phase 2(1)

Phase 4(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT00764036Phase 1Completed

Study of Artesunate in Metastatic Breast Cancer

Role: collaborator

NCT01054651Phase 3Completed

A Randomised Trial of Artesunate-sulfamethoxypyrazine/Pyrimethamine Versus Praziquantel for the Treatment of S. Mansoni

Role: collaborator

NCT00484900Phase 3Completed

Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria

Role: lead

NCT00529867Phase 4Completed

Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria

Role: lead

NCT00510159Phase 2Completed

Comparing Praziquantel Versus Artesunate + Sulfamethoxypyrazine/Pyrimethamine for Treating Schistosomiasis

Role: lead

All 5 trials loaded